

Company Name: Linical Co., Ltd.  
Representative: Kazuhiro Hatano  
President & CEO  
(TSE code: 2183)

March 18, 2026

## Notice Concerning Revision of the Results Forecast, Revision of Dividends Forecasts and Reduction of Executive Compensation

Linical Co., Ltd. (the Company) hereby informs that the Company has revised its consolidated results forecast for the fiscal year ending March 2026 (April 1, 2025 to March 31, 2026), which was announced on November 14, 2025, and dividends forecasts announced on May 15, 2025 as follows. In addition, the Company has resolved to reduce executive compensation as outlined below.

### 1. Revision of consolidated earnings forecasts

- (1) Revision of the consolidated results forecast for the fiscal year ending March 2026 (April 1, 2025 - March 31, 2026)

(Unit: million yen)

	Sales	Operating profit	Ordinary profit	Net profit attributable to owners of the parent	Net profit per share
Previously announced forecast (A)	9,350	△1,350	△1,400	△1,700	△75.27 yen
Revised forecast (B)	8,663	△2,138	△2,101	△2,377	△105.24 yen
Change (B-A)	△687	△788	△701	△677	
Change (%)	△7.3	—	—	—	
(Reference) Results for the previous fiscal year (Fiscal year ended March 2025)	10,437	△583	△498	△539	△23.87 yen

### (2) Reason for the revision

The Company has revised its full-year consolidated earnings forecast, originally announced on November 14, 2025, for the following reasons:

Sales are expected to fall short of the initial plan and come in below expectations, making it necessary to revise our forecasts for Sales, Operating profit, Ordinary profit, and Net profit attributable to owners of the parent.

In Japan, certain projects for which we had aimed to secure orders in the second half did not reach our targets, and results are expected to be lower than initially anticipated. In Europe and the United States, we had expected to win several large-scale global clinical trials, including those in the U.S., Europe, and Australia, and to commence them within the current fiscal year. However, mainly due to delays in the commencement of most of these trials arising from the impact of a shutdown of U.S. government agencies and delays in preceding clinical trials, performance is expected to be lower than initially anticipated.

In Europe and the United States, we expect the aforementioned several large-scale global clinical trials, including those in the U.S., Europe, and Australia, to move into full-scale operations from the next fiscal year. In addition, we have recently secured several further large-scale projects, and expectations are increasing for the selection of contract research organizations for multiple new projects that had been stalled due to the impact of U.S. government agencies, among other factors. We will continue to implement all possible measures to improve our performance.

(Note)

The above forecast is based on information that the company has obtained at the present time and certain assumptions judged to be reasonable. Actual results may differ greatly from the forecast due to various factors.

## 2. Revision of dividends forecasts

(1) Forecast of cash dividends for the fiscal year ending March 2026 (April 1, 2025 - March 31, 2026)

(yen)

	Dividend per share		
	Interim	Year-end	Total
Previously announced forecast	—	16.00	16.00
Revised forecast	—	8.00	8.00
Actual result	0.00		
Fiscal year ended March 31, 2025	0.00	16.00	16.00

(2) Reason for the revision

The Company's basic policy is to optimize the balance between the improvement in our corporate value through mid/long-term growth and return to shareholders, and we aim to return profits in a stable manner with consideration of business performance.

Under this policy, and in light of the revision to the results forecasts announced at this time, we are revising our forecasts for the year-end dividends, decreasing by 8.00 yen from the forecasts announced on May 15, 2025. As a result, the revised annual dividends will be 8.00 yen per share.

3. Reduction of Executive Compensation

The Board of Directors has resolved to reduce executive compensation as outlined below, in recognition of the downward revision of the results forecast and dividends forecasts, and to clarify management accountability.

(1) Details of the Reduction

Representative Director and President & CEO	30% reduction in monthly compensation
CXO (Chief x Officer)	20% reduction in monthly compensation
Executive Officer	10% reduction in monthly compensation

(2) Period of Reduction

From April 2026 to June 2026 (3 months)

The entire management team is fully committed to making every effort to restore business performance and achieve future growth. We sincerely appreciate the continued support of our shareholders and all other stakeholders.

End

(Note)

This is a translation of the press release originally drafted in Japanese for the disclosure required in compliance with the TSE regulations.